Tedizolid, Dalbavancin Still Face Questions On ABSSSI Lesion Measurement
Executive Summary
Both antibiotics gain a strong positive recommendation from FDA advisory committee, but questions about how skin lesions were measured before and during treatment persist as experience with new endpoint increases.